Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

In the past seven trading days, the stock price of Cipla has slipped 11 per cent from ₹1,530.25 hit on January 1, 2026.

Cipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek ...

Regulatory action at Pharmathen’s main manufacturing site in Greece could potentially disrupt supplies of one of Cipla’s ...

Cipla had earlier received final USFDA approval in May 2024 to market its generic Lanreotide injection in multiple strengths.

In its communication, Cipla stated that Pharmathen International S.A., based in Greece, manufactures and exclusively supplies ...

Cipla shares fell over 4 per cent after brokerage downgraded the stock to Reduce, citing weak near-term earnings visibility ...

Cipla clarified that its supply partner Pharmathen received nine USFDA Form 483 observations during a November 2025 ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...